Mirus Bio

Investigators from Arrowhead Research this week published data on a novel strategy of administering a cholesterol-conjugated siRNA payload independently from its delivery vehicle, showing that the co-delivery method can achieve significant gene target knockdown in non-human prima

The program will run through 2012 and provide eligible labs with $5,000, $3,000, or $2,000 worth of Mirus products, as well as technical support.

Meanwhile, the Swiss drugs and diagnostics giant is taking a measured approach to the related but nascent microRNA field, exploring partnerships with key miRNA companies and doing a certain amount of research on its own, yet keeping most of its attention focused on RNAi.